Glenmark Pharmaceuticals informs about press release

03 Sep 2015 Evaluate

Glenmark Pharmaceuticals has informed about a Press Release dated September 03, 2015 titled ‘Glenmark’s novel monoclonal antibody GBR 830 to enter Phase 2 clinical studies in Atopic Dermatitis and Celiac Disease in US and Europe’.

The above information is a part of company’s filings submitted to BSE.


 

Glenmark Pharma Share Price

2052.00 26.60 (1.31%)
02-Jan-2026 12:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1725.10
Dr. Reddys Lab 1249.75
Cipla 1509.25
Zydus Lifesciences 915.50
Lupin 2097.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×